Baxter (NYSE:BAX) announced late last week that it finally sealed the deal on its $3.9 billion acquisition of Swedish dialysis giant Gambro AB, closing the books on a deal months in the making.
Mergers & Acquisitions
Aussie regulators approve Baxter’s $4B Gambro merger
Rochester Medical skyrockets on $262M Bard acquisition news
Advance Medical raises $20M, buys Brazilian rival and scoops execs from GE, Sanofi
Advance Medical had a big week, raising $20 million through a new equity financing round, nabbing all the assets of rival Brazilian distributor Imunotech Sistemas and adding a pair of medtech veterans to its team.
China probes medtech pricing | Wall Street Beat
The Chinese Commerce Ministry’s anti-monopoly bureau is looking for information on pricing and operations at medical device makers within the country as well as from around the world, according to a Reuters report.
Local sources told the new service that concerns about local corruption and price-fixing may have spurred the survey, but a deputy director at the China Assn. for Medial Devices Industry told reporters that there hadn’t been word of any official investigations into the sector.
LeMaitre Vascular scoops up InaVein for $2.5M
LeMaitre Vascular (NSDQ:LMAT) is jumping into the varicose vein removal business with a $2.5 million buyout of InaVein. The Burlington, Mass.-based vascular device maker snatched up InaVein for more than 100% more than the company’s 2012 sales, according to a company statement.
Medtronic hands Pioneer Plus catheters to Volcano in closed-doors deal
Abbott closes $310M IDEV Technologies buy
Baxter appeases EU regulators in $4B Gambro buyout
Medafor agrees to Bard buyout worth up to $280M
C.R. Bard (NYSE:BCR) said it agreed to pay $200 million up front and another possible $80 million for Medafor and its line of anti-bleeding agents.
Minneapolis-based Medafor makes plant-based hemostatic agents including the Arista MPH agent, which won CE Mark approval in the European Union in 2003 and garnered FDA approval for surgical use in 2006.
Abbott closes OptiMedica buyout
Abbott (NYSE:ABT) said it closed the buyout of OptiMedica Corp. it announced in July, paying $250 million up front with another $150 million on the table if development, regulatory and sales milestones are met.
The buyout expands the Chicago-area healthcare giant’s Abbott Medical Optics ophthalmology unit by adding femtosecond laser-assisted cataract surgery to its portfolio.